PACS · PACS Group, Inc.
Market Cap
$6.77B
Shares
158.34M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$42.75
Open$44.34
Day$42.75–44.61
52W close$7.71–48.45
Avg vol 30d806K
Short int3.6M · 2.3% float · 3.6d
Short vol55%
Last earningsAug 5, 2026
DataApr 2024–Aug 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+16%
above
Price vs 50-day avg
−3%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
86%
near high
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−7%
trailing
6-month return
+25%
trailing
YTD return
+11%
this year
Relative strength
+12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $44 › 200d $37 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$155.3K over 90 days · 100% sells
Short interest
Falling
2.26% of float · ▼ -6.2% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
243 holders — near 2-yr high, broad support
Squeeze score
47
elevated · 0–100
Fundamentals
Revenue growth
+29%
Y/Y
EPS growth
+221%
Y/Y
Buyback
$250.0M
remaining
Balance sheet
$156.2M
net debt
Quant / Vol
risk profile
Volatility
102%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Adjusted EBITDA
· full-year 2026
Non-GAAP
Raised
$640M – $660M
May 11, 2026
$605M – $625M
changed to
Aug 4, 2026
$640M – $660M
Revenue
· full-year 2026
Raised
$5.75B – $5.85B
May 11, 2026
$5.65B – $5.75B
changed to
Aug 4, 2026
$5.75B – $5.85B
prior FY $5.29B
midpoint +9.7% Y/Y
Prior guidance
period ended
· from the 8-K filed Nov 19, 2025
Revenue
· full year 2025
$5.25B – $5.35B
Adjusted EBITDA
· full year 2025
$480M – $490M
Guided vs delivered
· last 1 settled
Revenue
full year 2025
guided $5.25B – $5.35B
$5.29B
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+16%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
86%
Bullish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $44 › 200d $37 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +58 funds added
Insider flow
Distributing
Net -$155.3K over 90 days · 100% sells
Short interest
Falling
2.26% of float · ▼ -6.2% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
243 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $8
Now $43 · 86%
Range high $48
vs 200-day avg +16%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Actual patient days | 2,697,638 | the three months ended June 30, 2026 filing | — |
|
|
|||
| Adjusted EBITDA non-GAAP | $166.8M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP EBITDA 132.02M
+734K Acquisition related costs
+25.83M Stock-based compensation expense
+8.17M Legal and other costs
= Adjusted EBITDA 166.75M
|
|||
| Adjusted EBITDAR non-GAAP | $261.5M | Q2 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Adjusted EBITDA 166.75M
+94.7M Rent - cost of services
= Adjusted EBITDAR 261.45M
|
|||
| Available liquidity | $756.6M | As of June 30, 2026 | — |
| Available patient days | 2,983,890 | the three months ended June 30, 2026 filing | — |
|
|
|||
| Healthcare operations (portfolio) | 344 | As of August 1, 2026 | — |
| Leased facilities with partial ownership in real estate | 49 | As of August 1, 2026 | — |
| Mature facilities CMS Quality Measure Star rating (average) | 4.5 | Q2 2026 | — |
|
|
|||
| Mature facilities occupancy | 93.8% | Q2 2026 | — |
|
|
|||
| Mature facilities skilled mix | 31.9% | Q2 2026 | — |
|
|
|||
| Number of facilities at period end | 290 | the three months ended June 30, 2026 filing | — |
| Number of facilities with 4 or 5 star CMS Quality Measure Star rating | 239 | Q2 2026 | — |
|
|
|||
| Number of operational beds at period end | 32,790 | the three months ended June 30, 2026 filing | — |
| Occupancy (same-store SNFs) | 90.6% | Q2 2026 | — |
|
|
|||
| Occupancy rate (operational beds) | 90.4% | the three months ended June 30, 2026 filing | — |
| Overall occupancy | 90.4% | Q2 2026 | — |
|
|
|||
| Overall skilled mix | 30% | Q2 2026 | — |
| Owned facilities | 64 | As of August 1, 2026 | — |
| Patients served daily | 33,400 | As of August 4, 2026 | — |
| Purchase options on leased facilities | 36 | As of August 1, 2026 | — |
| Purchase options through partnerships | 20 | As of August 1, 2026 | — |
| Same-store SNF revenue growth | 5.8% | Q2 2026 | — |
|
|
|||
| Same-store SNFs | 284 | Q2 2026 | — |
| Skilled mix by nursing patient days | 30% | the three months ended June 30, 2026 filing | — |
|
|
|||
| Skilled mix by patient days (same-store) | 29.7% | the three months ended June 30, 2026 filing | — |
| Skilled mix by revenue | 50% | the three months ended June 30, 2026 filing | — |
|
|
|||
| Number of facilities at period end (Total) | 324 | as of today | — |
| Ramping facilities occupancy | 88.9% | first quarter of 2026 | — |
| Skilled mix - Total | 30.5% | first quarter of 2026 | — |
| Assisted living and independent living units added | 271 | Full Year 2025 | — |
| EBITDA non-GAAP | $368.56M | Year ended December 31, 2025 | — |
GAAP → non-GAAP reconciliationGAAP Net income 191.46M
-82K Less: Net (loss) income attributable to noncontrolling interest
+28.36M Add: Interest expense
+92.99M Provision for income taxes
+55.66M Depreciation and amortization
= EBITDA 368.56M
|
|||
| Facilities with 4 or 5 star CMS Quality Measure Star rating | 207 | Full Year 2025 | — |
| Number of facilities at period end (Mature) | 149 | Year ended December 31, 2025 | — |
| Number of facilities at period end (New) | 78 | Year ended December 31, 2025 | — |
| Number of facilities at period end (Ramping) | 64 | Year ended December 31, 2025 | — |
| Number of operational beds at period end (Mature) | 16,415 | Year ended December 31, 2025 | — |
| Number of operational beds at period end (New) | 8,153 | Year ended December 31, 2025 | — |
| Number of operational beds at period end (Ramping) | 8,286 | Year ended December 31, 2025 | — |
| Occupancy rate (operational beds) (Mature) | 94.9% | Year ended December 31, 2025 | — |
| Occupancy rate (operational beds) (New) | 81.1% | Year ended December 31, 2025 | — |
| Occupancy rate (operational beds) (Ramping) | 86.3% | Year ended December 31, 2025 | — |
| Operating facilities added during 2025 | 8 | Full Year 2025 | — |
| Skilled mix by nursing days | 28.7% | Year ended December 31, 2025 | — |
| Skilled mix by nursing revenue | 48.8% | Year ended December 31, 2025 | — |
| Skilled nursing beds added | 655 | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PACS
this stock
PACS Group, Inc.
|
$6.77B | +11.4% | +29.3% | — | 2.3% |
|
HCA
HCA Healthcare, Inc.
|
$92.69B | -10.5% | +7.1% | 14.4 | 2.8% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$30.05B | -6.9% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.48B | +34.3% | +0.9% | 10.3 | 3.1% |
|
FMS
Fresenius Medical Care AG
|
$12.29B | -3.0% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PACS | -3.4% | -7.1% | +25.4% | -7.1% | +11.4% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -3.9% | -10.1% | +12.0% | -10.1% | -1.5% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$250.00M
Spent (derived)
$0
Remaining
$250.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
2001184
CUSIP
69380Q107
13F (30d)
192 filings
190 filers
Visit website
Investor relations